Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17676964 | 1.00 | SCN4A (0.47) | SCN4APRCPEPHX1NPC1RAB9A | |
| SCHEMBL3333289 | 1.00 | SCN4A (0.47) | SCN4APRCPEPHX1NPC1RAB9A | |
| SCHEMBL9825084 | 0.98 | EPHX1 (0.48) | SCN4APRCPEPHX1NPC1RAB9A | |
| SCHEMBL7265700 | 0.98 | EPHX1 (0.48) | SCN4APRCPEPHX1NPC1RAB9A | |
| SCHEMBL5157107 | 0.98 | EPHX1 (0.48) | SCN4APRCPEPHX1NPC1RAB9A | |
| SCHEMBL17676973 | 0.98 | EPHX1 (0.48) | SCN4APRCPEPHX1NPC1RAB9A | |
| SCHEMBL953074 | 0.96 | SCN4A (0.47) | SCN4APRCPEPHX1NPC1RAB9A | |
| SCHEMBL3633992 | 0.96 | SCN4A (0.47) | SCN4APRCPEPHX1NPC1RAB9A | |
| SCHEMBL9824982 | 0.94 | EPHX1 (0.48) | SCN4APRCPEPHX1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3327729 | 0.94 | SCN4A (0.49) | SCN4APRCPEPHX1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210949-A1 | LIQUID FORMULATION | HANMI PHARM CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| WO-2011108672-A2 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | 高砂香料工業株式会社 (JP) | 2011-09-09 | — | — | WO | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| WO-2010140636-A1 | ASYMMETRIC HYDROGENATION CATALYST | 高砂香料工業株式会社 (JP) | 2010-12-09 | — | — | WO | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | SCN4A 2538/4885PRCP 4634/4885EPHX1 1122/4885 |
| US-20230210949-A1 | LIQUID FORMULATION | GLP1R, GIPR, SSTR5 | SCN4A 2260/4885PRCP 1036/4885EPHX1 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.